Regeneron News and Research

RSS
European Commission approves EYLEA Injection for treatment of visual impairment due to DME

European Commission approves EYLEA Injection for treatment of visual impairment due to DME

Regeneron announces FDA approval of EYLEA Injection for DME treatment

Regeneron announces FDA approval of EYLEA Injection for DME treatment

FDA approves EYLEA Injection for treatment of Diabetic Macular Edema

FDA approves EYLEA Injection for treatment of Diabetic Macular Edema

Phase 3 VIVID-DME trial of EYLEA Injection for treatment of DME shows improvement in visual acuity

Phase 3 VIVID-DME trial of EYLEA Injection for treatment of DME shows improvement in visual acuity

Regeneron, Sanofi report positive results from dupilumab Phase 2b study in moderate-to-severe AD

Regeneron, Sanofi report positive results from dupilumab Phase 2b study in moderate-to-severe AD

Bayer HealthCare seeks EU marketing authorization of EYLEA for macular edema following BRVO

Bayer HealthCare seeks EU marketing authorization of EYLEA for macular edema following BRVO

Controlling low-density lipoprotein-cholesterol levels: an interview with Jay Edelberg, M.D., Sanofi and Bill Sasiela, Ph.D., Regeneron

Controlling low-density lipoprotein-cholesterol levels: an interview with Jay Edelberg, M.D., Sanofi and Bill Sasiela, Ph.D., Regeneron

Bayer Yakuhin submits marketing authorization application in Japan for EYLEA Injection

Bayer Yakuhin submits marketing authorization application in Japan for EYLEA Injection

Regeneron receives FDA acceptance for EYLEA injection for treatment of macular edema

Regeneron receives FDA acceptance for EYLEA injection for treatment of macular edema

Sanofi and Regeneron Pharmaceuticals team up with ACC to enhance clinical research with alirocumab

Sanofi and Regeneron Pharmaceuticals team up with ACC to enhance clinical research with alirocumab

FDA accepts Regeneron's EYLEA Injection sBLA for standard review

FDA accepts Regeneron's EYLEA Injection sBLA for standard review

EYLEA Injection gets approval in Japan for treatment of macular edema following CRVO

EYLEA Injection gets approval in Japan for treatment of macular edema following CRVO

Regeneron announces topline results from Phase 3 study of EYLEA Injection in patients with Macular Edema following BRVO

Regeneron announces topline results from Phase 3 study of EYLEA Injection in patients with Macular Edema following BRVO

Phase 3 ODYSSEY MONO trial with alirocumab meets primary efficacy endpoint

Phase 3 ODYSSEY MONO trial with alirocumab meets primary efficacy endpoint

European Commission approves EYLEA for treatment of visual impairment due to macular edema following CRVO

European Commission approves EYLEA for treatment of visual impairment due to macular edema following CRVO

Regeneron, Bayer report positive results from Phase 3 VIVID-DME and VISTA-DME trials of EYLEA for DME

Regeneron, Bayer report positive results from Phase 3 VIVID-DME and VISTA-DME trials of EYLEA for DME

Eylea can ease vision problems for wet AMD patients

Eylea can ease vision problems for wet AMD patients

Sanofi, Regeneron enroll patients in two sarilumab Phase 3 trials for treatment of RA

Sanofi, Regeneron enroll patients in two sarilumab Phase 3 trials for treatment of RA

Regeneron Pharmaceuticals expands ophthalmology portfolio

Regeneron Pharmaceuticals expands ophthalmology portfolio

NCRI, Prize4Life recognized with Bio-IT World's Best Practices Award for creating PRO-ACT platform

NCRI, Prize4Life recognized with Bio-IT World's Best Practices Award for creating PRO-ACT platform